Observing the effectiveness and safety of Reditux and Reference Medicinal Product(s) to treat Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukaemia

2019 ◽  
Author(s):  
Rakesh Naranbhai Dadhania
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
B Cell ◽  
Medicinal Product ◽  
Lymphocytic Leukaemia ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Two distinct histological Richter’s transformations 23 years apart in a patient with chronic lymphocytic leukaemia

2018 ◽  
pp. bcr-2018-225893 ◽  
Author(s):  
Umera Thebo ◽  
Ralph Linwood Millett ◽  
Jacob Elkon ◽  
Faysal Haroun
Keyword(s):  
Lymph Node ◽  
Chronic Lymphocytic Leukaemia ◽  
Cervical Lymph Node ◽  
Lymphocytic Leukaemia ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Ann Arbor ◽  
History Of ◽  
Large B Cell

A 53-year-old man with a 1-year history of chronic lymphocytic leukaemia (CLL) presented with a left bicep mass. Biopsy and staging workup revealed Richter’s transformation (RT) Ann Arbor stage 1E diffuse large B-cell lymphoma in the bicep. The patient was treated with combination chemotherapy with cyclophosphamide, doxorubicin, Vincristine and prednisone followed by site radiation and did well thereafter. His CLL progressed and required treatment on two more occasions 11 and 18 years after his initial diagnosis with fludarabine, Cytoxan and Rituxan and then with bendamustine and rituximab. 23 years after initial presentation, he developed diffuse lymphadenopathy and B-symptoms. A biopsy of an enlarged cervical lymph node demonstrated only CLL for which he was started on ibrutinib. Treatment was shortly discontinued thereafter due to intolerance and worsening symptoms. A second biopsy was performed which revealed concurrent CLL and Hodgkin’s lymphoma representing a second and histologically distinct RT.

scholarly journals Epstein-Barr virus negative large B-cell lymphoma during long term immunomodulatory therapy for T-cell large granular lymphocytic leukaemia

2010 ◽  
Vol 148 (2) ◽  
pp. 337-339 ◽  
Author(s):  
Parameswaran Anoop ◽  
Girish Ravindranathan ◽  
Nnenna Osuji ◽  
Claire E. Dearden ◽  
Andy Wotherspoon ◽  
...  
Keyword(s):  
B Cell ◽  
Epstein Barr Virus ◽  
Lymphocytic Leukaemia ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Barr Virus ◽  
Large B Cell Lymphoma ◽  
Epstein Barr ◽  
Large B Cell

Lymphome

Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Staging System ◽  
Maligne Lymphome ◽  
Interim Pet ◽  
Large B Cell Lymphoma ◽  
Ann Arbor ◽  
Large B Cell

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.

Sign in / Sign up

Export Citation Format

Share Document